Zomedica (NYSEAMERICAN:ZOM) Stock Price Down 4.3%

Zomedica Corp. (NYSEAMERICAN:ZOM)’s share price dropped 4.3% during mid-day trading on Friday . The company traded as low as $0.12 and last traded at $0.12. Approximately 6,579,362 shares changed hands during mid-day trading, an increase of 25% from the average daily volume of 5,268,323 shares. The stock had previously closed at $0.13.

Zomedica Price Performance

Zomedica (NYSEAMERICAN:ZOM) last released its earnings results on Monday, April 1st. The company reported ($0.01) earnings per share (EPS) for the quarter. Zomedica had a negative net margin of 137.10% and a negative return on equity of 8.13%. The company had revenue of $7.34 million during the quarter, compared to analysts’ expectations of $7.00 million.

Institutional Investors Weigh In On Zomedica

Institutional investors have recently bought and sold shares of the business. Morgan Stanley grew its stake in Zomedica by 54.8% during the fourth quarter. Morgan Stanley now owns 435,790 shares of the company’s stock worth $71,000 after buying an additional 154,222 shares during the period. UBS Group AG grew its stake in Zomedica by 207.6% during the first quarter. UBS Group AG now owns 200,000 shares of the company’s stock worth $67,000 after buying an additional 134,984 shares during the period. Commonwealth Equity Services LLC boosted its stake in shares of Zomedica by 27.9% in the first quarter. Commonwealth Equity Services LLC now owns 275,175 shares of the company’s stock valued at $58,000 after purchasing an additional 60,000 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Zomedica by 76.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 332,000 shares of the company’s stock valued at $54,000 after purchasing an additional 144,000 shares in the last quarter. Finally, Jane Street Group LLC grew its holdings in Zomedica by 62.9% during the 4th quarter. Jane Street Group LLC now owns 269,728 shares of the company’s stock valued at $44,000 after purchasing an additional 104,143 shares in the last quarter. 8.95% of the stock is currently owned by hedge funds and other institutional investors.

Zomedica Company Profile

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.